Novo Nordisk A/S (NYSE:NVO – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat reports. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $145.67.
Several equities research analysts recently weighed in on the company. Argus boosted their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Monday, June 17th. The Goldman Sachs Group began coverage on shares of Novo Nordisk A/S in a research report on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price on the stock. Finally, BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target for the company.
Get Our Latest Stock Report on Novo Nordisk A/S
Institutional Investors Weigh In On Novo Nordisk A/S
Novo Nordisk A/S Trading Up 0.7 %
Shares of NYSE:NVO opened at $141.95 on Friday. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $144.50. The company’s 50 day moving average is $132.94 and its two-hundred day moving average is $121.73. The company has a market cap of $637.00 billion, a PE ratio of 48.95, a P/E/G ratio of 1.40 and a beta of 0.41. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17.
Novo Nordisk A/S (NYSE:NVO – Get Free Report) last posted its earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.77 by $0.06. The firm had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. Equities analysts predict that Novo Nordisk A/S will post 3.41 earnings per share for the current fiscal year.
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
See Also
- Five stocks we like better than Novo Nordisk A/S
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Sarepta Therapeutics Stock Soars on FDA Approval
- Consumer Discretionary Stocks Explained
- CarMax: A Market Melt-Up Waiting to Happen for this Stock
- Canada Bond Market Holiday: How to Invest and Trade
- 3 Solar Stocks to Watch that are Building the Green Energy Future
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.